Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System

Study summary

The purpose of this study is to learn what cancer patients think about IBM Watson Oncology. IBM Watson Oncology is a computer program designed to help inform oncologists about the best chemotherapy choices for their patients. The investigators will conduct focus groups with cancer patients who have received chemotherapy treatment at MSK in order to understand cancer patients' thoughts about IBM Watson Oncology.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedFocus groups

The study team can explain what participation involves.

Who it may be forBreast Cancer · Lung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 25, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Memorial Sloan Kettering Cancer Center
Interventions being studied: Behavioral: Focus groups

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Chemotherapy→Supportive or behavioral care→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

MSKCC patient 18 years or older
Breast, lung, or colorectal cancer MSK patient as per EMR or clinician judgment having either:
Chemotherapeutic adjuvant or neoadjuvant treatment with the first chemo visit occurring within the past 8 months and primary treatment (i.e., surgery), occurring within the past 6 months)at MSK
OR chemotherapeutic treatment for metastatic disease with the first chemo visit occurring within the past 8 months at MSK
OR chemotherapeutic treatment through an on-going MSK clinical trial as per clinician
Residing in New York metro-area

Reasons someone may not be able to joinExclusion criteria

Non-English speakers because we do not have the resources to conduct and translate the focus groups into other languages
Patients who are not or will not receive their cancer care at MSKCC.
Patient unwilling or unable to provide informed consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Memorial Sloan Kettering Cancer CenterNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 25, 2020. Always confirm current availability with the study team.

View original record ↗